Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering GMP investigation

Executive Summary

FDA/Justice Department investigation of Schering-Plough's GMP compliance at its Manati, P.R. facility is focusing on ribavirin, among other products, firm discloses. The investigation itself was disclosed in May; Schering has not previously identified specific products targeted (1"The Pink Sheet" June 24, 2002, In Brief)...

You may also be interested in...



Schering GMP investigation

The Newark, N.J. U.S. Attorney's Office is spearheading a criminal investigation related to Schering-Plough's Puerto Rico production facilities, Schering confirms (1"The Pink Sheet" May 20, p. 5). The investigation reportedly focuses on use of unapproved raw materials...

Brazil Levels Medtech ICT Tariffs Playing Field

All medtech in Brazil will soon be subject to standardized industrial tariffs and development-related fiscal incentives, following a reform of rules relating to ICT across all industries.

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

UsernamePublicRestriction

Register

PS041447

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel